181 related articles for article (PubMed ID: 27995649)
1. Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants.
Sohn JA; Kim HS; Oh J; Cho JY; Yu KS; Lee J; Shin SH; Lee JA; Choi CW; Kim EK; Kim BI; Park EA
Br J Clin Pharmacol; 2017 Jun; 83(6):1279-1286. PubMed ID: 27995649
[TBL] [Abstract][Full Text] [Related]
2. Developmental changes in urinary elimination of theophylline and its metabolites in pediatric patients.
Tateishi T; Asoh M; Yamaguchi A; Yoda T; Okano YJ; Koitabashi Y; Kobayashi S
Pediatr Res; 1999 Jan; 45(1):66-70. PubMed ID: 9890610
[TBL] [Abstract][Full Text] [Related]
3. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans.
Rasmussen BB; Brøsen K
Br J Clin Pharmacol; 1997 Mar; 43(3):253-8. PubMed ID: 9088579
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of aciclovir on metabolism of theophylline and expression of hepatic cytochrome P450 1A2 in rats.
Nadai M; Kato M; Yasui K; Kimura M; Zhao YL; Ueyama J; Tsunekawa Y; Yoshizumi H; Hasegawa T
Biol Pharm Bull; 2007 Mar; 30(3):562-8. PubMed ID: 17329857
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous quantitation of serum caffeine and its metabolites by ultra-high-performance liquid chromatography-tandem mass spectrometry for CYP1A2 activity prediction in premature infants.
Jiang Z; Gao X; Liang J; Ni S
Biomed Chromatogr; 2021 Sep; 35(9):e5141. PubMed ID: 34041763
[TBL] [Abstract][Full Text] [Related]
6. Severe 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) intoxication: insights into the measurement of hepatic cytochrome P450 1A2 induction.
Abraham K; Geusau A; Tosun Y; Helge H; Bauer S; Brockmöller J
Clin Pharmacol Ther; 2002 Aug; 72(2):163-74. PubMed ID: 12189363
[TBL] [Abstract][Full Text] [Related]
7. The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients.
Uslu A; Ogus C; Ozdemir T; Bilgen T; Tosun O; Keser I
BMB Rep; 2010 Aug; 43(8):530-4. PubMed ID: 20797314
[TBL] [Abstract][Full Text] [Related]
8. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.
Takata K; Saruwatari J; Nakada N; Nakagawa M; Fukuda K; Tanaka F; Takenaka S; Mihara S; Marubayashi T; Nakagawa K
Eur J Clin Pharmacol; 2006 Jan; 62(1):23-8. PubMed ID: 16385402
[TBL] [Abstract][Full Text] [Related]
9. Plasma theophylline and caffeine and plasma clearance of theophylline during theophylline treatment in the first year of life.
Lönnerholm G; Lindström B; Paalzow L; Sedin G
Eur J Clin Pharmacol; 1983; 24(3):371-4. PubMed ID: 6861850
[TBL] [Abstract][Full Text] [Related]
10. Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants.
al-Omran A; al-Alaiyan S
Am J Perinatol; 1997 Mar; 14(3):147-9. PubMed ID: 9259917
[TBL] [Abstract][Full Text] [Related]
11. Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine.
Orlando R; Padrini R; Perazzi M; De Martin S; Piccoli P; Palatini P
Clin Pharmacol Ther; 2006 May; 79(5):489-99. PubMed ID: 16678550
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of theophylline in premature Korean infants.
Kim SE; Kim BH; Lee S; Sohn JA; Kim HS; Cho JY; Yoon SH; Jang IJ; Yu KS; Lim KS
Ther Drug Monit; 2013 Jun; 35(3):338-44. PubMed ID: 23666573
[TBL] [Abstract][Full Text] [Related]
13. Renal clearance of theophylline and its major metabolites: age and urine flow dependency in paediatric patients.
Bonnacker I; Berdel D; Süverkrüp R; von Berg A
Eur J Clin Pharmacol; 1989; 36(2):145-50. PubMed ID: 2721539
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
Macias WL; Bergstrom RF; Cerimele BJ; Kassahun K; Tatum DE; Callaghan JT
Pharmacotherapy; 1998; 18(6):1237-48. PubMed ID: 9855322
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of theophylline in very premature Japanese infants with apnoea.
Fukuda T; Yukawa E; Kondo G; Maeda T; Shin-o T; Kondo Y; Imamura T; Irikura M; Irie T
J Clin Pharm Ther; 2005 Dec; 30(6):591-6. PubMed ID: 16336292
[TBL] [Abstract][Full Text] [Related]
16. Theophylline pharmacokinetics: comparison of Cyp1a1(-/-) and Cyp1a2(-/-) knockout mice, humanized hCYP1A1_1A2 knock-in mice lacking either the mouse Cyp1a1 or Cyp1a2 gene, and Cyp1(+/+) wild-type mice.
Derkenne S; Curran CP; Shertzer HG; Dalton TP; Dragin N; Nebert DW
Pharmacogenet Genomics; 2005 Jul; 15(7):503-11. PubMed ID: 15970798
[TBL] [Abstract][Full Text] [Related]
17. [Effect of Tibetan medicine zuotai on the activity, protein and mRNA expression of CYP1A2 and NAT2].
Li XY; Liu YN; Li YP; Zhu JB; Yao XC; Li YF; Yang M; Yuan M; Fan XR; Yin YM
Yao Xue Xue Bao; 2014 Feb; 49(2):267-72. PubMed ID: 24761621
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of interaction between theophylline and mexiletine.
Ueno K; Miyai K; Kato M; Kawaguchi Y; Suzuki T
DICP; 1991; 25(7-8):727-30. PubMed ID: 1949927
[TBL] [Abstract][Full Text] [Related]
19. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow.
Sinués B; Sáenz MA; Lanuza J; Bernal ML; Fanlo A; Juste JL; Mayayo E
Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):159-66. PubMed ID: 10067814
[TBL] [Abstract][Full Text] [Related]
20. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
